Cancer risk in relatives of patients with a primary disorder of lymphocyte cytotoxicity: a retrospective cohort study

The Lancet Haematology

Volumn 2, Issue 12, 2015, Pages e536-e542

  Löfstedt, Alexandra ^a   Chiang, Samuel C C ^a   Onelöv, Erik ^a   Bryceson, Yenan T ^a   Meeths, Marie ^a   Henter, Jan Inge ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD3 ANTIGEN; CHROMIUM 51; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1;

ADOLESCENT; ADULT; ARTICLE; CANCER RISK; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE MUTATION; GENETIC SCREENING; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNOSURVEILLANCE; INFANT; LYMPHOCYTOTOXICITY; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NEWBORN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; AGED; CASE CONTROL STUDY; FAMILY HEALTH; GENETICS; INCIDENCE; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MIDDLE AGED; NEOPLASMS; REGISTER; RISK FACTOR; SWEDEN; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHILD; COHORT STUDIES; FAMILY HEALTH; FEMALE; HUMANS; INCIDENCE; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; MIDDLE AGED; NEOPLASMS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SWEDEN; YOUNG ADULT;

EID: 84997207490     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(15)00223-9     Document Type: Article

References (30)

1. 1 Boyle, P, Levin, B, World cancer report 2008, 2008, IARC Press, International Agency for Research on Cancer, Lyon.
2. 2 Peto, J, Cancer epidemiology in the last century and the next decade. Nature 411 (2001), 390–395.
3. 3 Groden, J, Thliveris, A, Samowitz, W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66 (1991), 589–600.
4. 4 Venkitaraman, AR, Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108 (2002), 171–182.
5. 5 Chow, E, Thirlwell, C, Macrae, F, Lipton, L, Colorectal cancer and inherited mutations in base-excision repair. Lancet Oncol 5 (2004), 600–606.
6. 6 Kriege, M, Brekelmans, CTM, Boetes, C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351 (2004), 427–437.
7. 7 Hanahan, D, Weinberg, RA, Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
8. 8 Vesely, MD, Kershaw, MH, Schreiber, RD, Smyth, MJ, Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29 (2011), 235–271.
9. 9 Dunn, G, Bruce, A, Ikeda, H, Old, L, Schreiber, R, Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3 (2002), 991–998.
10. 10 Vajdic, CM, Mao, L, van Leeuwen, MT, Kirkpatrick, P, Grulich, AE, Riminton, S, Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency?. Blood 116 (2010), 1228–1234.
11. 11 Voskoboinik, I, Trapani, JA, Perforinopathy: a spectrum of human immune disease caused by defective perforin delivery or function. Front Immunol, 4, 2013, 441.
12. 12 De Saint Basile, G, Ménasché, G, Fischer, A, Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nat Rev Immunol 10 (2010), 568–579.
13. 13 Smyth, MJ, Thia, KY, Street, SE, MacGregor, D, Godfrey, DI, Trapani, JA, Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 192 (2000), 755–760.
14. 14 Ciambotti, B, Mussolin, L, d' Amore, ESG, et al. Monoallelic mutations of the perforin gene may represent a predisposing factor to childhood anaplastic large cell lymphoma. J Pediatr Hematol Oncol 36 (2014), e359–e365.
15. 15 Chia, J, Yeo, KP, Whisstock, JC, Dunstone, MA, Trapani, JA, Voskoboinik, I, Temperature sensitivity of human perforin mutants unmasks subtotal loss of cytotoxicity, delayed FHL, and a predisposition to cancer. Proc Natl Acad Sci USA 106 (2009), 9809–9814.
16. 16 Clementi, R, Locatelli, F, Dupré, L, et al. A proportion of patients with lymphoma may harbor mutations of the perforin gene. Blood 105 (2005), 4424–4428.
17. 17 Machaczka, M, Klimkowska, M, Chiang, SCC, et al. Development of classical Hodgkin's lymphoma in an adult with biallelic STXBP2 mutations. Haematologica 98 (2013), 760–764.
18. 18 Rudd, E, Göransdotter Ericson, K, Zheng, C, et al. Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies. J Med Genet, 43, 2006, e14.
19. 19 Pagel, J, Beutel, K, Lehmberg, K, et al. Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lmphohistiocytosis type 5 (FHL5). Blood 119 (2012), 6016–6024.
20. 20 Meeths, M, Chiang, SCC, Wood, SM, et al. Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D. Blood 118 (2011), 5783–5793.
21. 21 Henter, J, Elinder, G, Söder, O, Öst, Å, Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr 80 (1991), 428–435.
22. 22 Meeths, M, Horne, A, Sabel, M, Bryceson, Y, Henter, J-I, Incidence of primary hemophagocytic lymphohistiocytosis in Sweden. Pediatr Blood Cancer, 2014, 10.1002/pbc.25308 published online Nov 8.
23. 23 Khan, S, Cancer incidence in Sweden 2011, 2012, The National Board of Health and Welfare, Stockholm, 1–115.
24. 24 Chiang, SCC, Theorell, J, Entesarian, M, et al. Comparison of primary human cytotoxic T-cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences in cytokine production. Blood 121 (2013), 1345–1356.
25. 25 Trapani, JA, Thia, KYT, Andrews, M, et al. Human perforin mutations and susceptibility to multiple primary cancers. Oncoimmunology, 2, 2013, e24185.
26. 26 Mehta, PA, Davies, SM, Kumar, A, et al. Perforin polymorphism A91V and susceptibility to B-precursor childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia 20 (2006), 1539–1541.
27. 27 Shapiro, RS, Malignancies in the setting of primary immunodeficiency: implications for hematologists/oncologists. Am J Hematol 86 (2011), 48–55.
28. 28 Dvorak, HF, Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315 (1986), 1650–1659.
29. 29 Grivennikov, SI, Greten, FR, Karin, M, Immunity, inflammation, and cancer. Cell 140 (2010), 883–899.
30. 30 Zur Hausen, H, Papillomaviruses in the causation of human cancers – a brief historical account. Virology 384 (2009), 260–265.